Product image of Milevoni (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Milevoni

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Milevoni (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Milevoni, is a combined oral contraceptive presented as a tablet for oral use. It is used to prevent pregnancy in women of reproductive age. GNH India supplies Milevoni as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratoire Ccd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Milevoni, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.
  • Prevention of pregnancy: provides reliable contraceptive protection for women of reproductive age.
  • Regulation of menstrual cycle: helps to stabilize bleeding patterns and reduce menstrual discomfort.
  • Treatment of acne: reduces androgen‑driven skin lesions in women when prescribed for this indication.

How It Works

  • Milevoni combines ethinylestradiol, a synthetic estrogen, with levonorgestrel, a progestogen. The estrogen component suppresses follicle‑stimulating hormone, while the progestogen inhibits luteinizing hormone surge, preventing ovulation. Additionally, levonorgestrel thickens cervical mucus and alters the endometrial lining, creating conditions unfavorable for fertilization and implantation.

Side Effects

Milevoni may cause a range of adverse reactions.

Common Side Effects

  • Nausea or gastrointestinal upset.
  • Breast tenderness or enlargement.
  • Headache or migraine.
  • Spotting or breakthrough bleeding.
  • Weight gain or fluid retention.
  • Mood changes or irritability.

Serious or Rare Side Effects

  • Deep vein thrombosis or pulmonary embolism.
  • Arterial thrombosis leading to stroke or myocardial infarction.
  • Severe allergic reaction (anaphylaxis).
  • Hepatic dysfunction or jaundice.
  • Hyperglycemia in diabetic patients.
  • Visual disturbances or eye pain.

Precautions & Warnings

  • Before prescribing Milevoni, clinicians should consider several safety factors.
  • Assess thrombotic risk: evaluate personal or family history of clotting disorders.
  • Avoid smoking: especially in women over 35 years of age.
  • Review liver function: contraindicated in severe hepatic disease.
  • Consider drug interactions: check concomitant medications that affect estrogen metabolism.
  • Pregnancy category: contraindicated in pregnancy (Category X).
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Avoid Interactions

Milevoni can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive efficacy.
  • Certain antiretrovirals (e.g., efavirenz): can lower hormone levels and increase risk of unintended pregnancy.
  • Additional estrogen‑containing therapies: increase risk of thrombotic events.

Moderate Interactions (Monitor Closely)

  • Antibiotics such as tetracycline or metronidazole: may slightly diminish absorption.
  • Antihypertensives (e.g., ACE inhibitors): monitor blood pressure as hormonal changes can affect control.
  • Herbal supplements like St. John’s wort: may decrease hormonal effectiveness, requiring additional contraceptive measures.

Frequently Asked Questions

Milevoni is a combined oral contraceptive indicated primarily for the prevention of pregnancy in women of reproductive age. It may also be prescribed to regulate menstrual cycles and to treat androgen‑related acne when clinically appropriate.

The ethinylestradiol component suppresses the release of follicle‑stimulating hormone, while levonorgestrel blocks the luteinizing hormone surge, together preventing ovulation. Levonorgestrel also thickens cervical mucus and alters the endometrial lining, creating an environment that hinders fertilisation and implantation.

The dosing regimen for Milevoni is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule and duration should follow the prescriber’s instructions.

Milevoni is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it may cause fetal harm. It is also not recommended for breastfeeding women unless the benefits outweigh the risks, as hormones can be excreted in breast milk.

To order Milevoni, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Milevoni contains the widely used estrogen‑progestin pair of ethinylestradiol and levonorgestrel, offering a balance of efficacy and tolerability comparable to other second‑generation combined pills. Its safety profile, dosing convenience, and regulatory approval align with standard expectations for this drug class.

Milevoni tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Milevoni is taken orally, usually as a single tablet each day. It should be swallowed with water, preferably at the same time each day, and not chewed or broken to ensure consistent absorption.

The most serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Women should seek immediate medical attention if they experience sudden leg pain, shortness of breath, chest pain, severe headache, or visual changes.

Milevoni is contraindicated in women who are pregnant, have a history of thromboembolic disorders, severe liver disease, known or suspected estrogen‑dependent tumors, or who are smokers over the age of 35. It should also be avoided in individuals with uncontrolled hypertension.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT